Economic evaluation in health (also known as pharmacoeconomic in case of medicines) identifies, measures, and values costs and outcomes of alternative healthcare technologies, and can be performed alongside controlled clinical trials, but analytical modelling is usually used. Decision trees and Markov models are the two most common approaches used in economic evaluation. The biggest advantages of a decision tree are clarity, simplicity, and straightforwardness. On the other hand, the main advantage of the Markov model is its ability to incorporate complex events into the simulation, which is practically impossible to do with a decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to promote availability and accessibility of the prescription medicines. To show current pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness analysis should be included. The latter should be conducted using appropriate modelling techniques. However, since no official methodological guidelines about the modelling and economic analysis exist, the submissions by marketing authorization holders vary greatly. The future of pharmacoeconomic modelling depends on the research area of interest, with new frameworks and approaches being developed.
{"title":"Modelling in economic evaluations of medicines","authors":"D. Lakic, I. Stević, M. Odalović, I. Tadić","doi":"10.5937/arhfarm71-32404","DOIUrl":"https://doi.org/10.5937/arhfarm71-32404","url":null,"abstract":"Economic evaluation in health (also known as pharmacoeconomic in case of medicines) identifies, measures, and values costs and outcomes of alternative healthcare technologies, and can be performed alongside controlled clinical trials, but analytical modelling is usually used. Decision trees and Markov models are the two most common approaches used in economic evaluation. The biggest advantages of a decision tree are clarity, simplicity, and straightforwardness. On the other hand, the main advantage of the Markov model is its ability to incorporate complex events into the simulation, which is practically impossible to do with a decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to promote availability and accessibility of the prescription medicines. To show current pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness analysis should be included. The latter should be conducted using appropriate modelling techniques. However, since no official methodological guidelines about the modelling and economic analysis exist, the submissions by marketing authorization holders vary greatly. The future of pharmacoeconomic modelling depends on the research area of interest, with new frameworks and approaches being developed.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In the present study, co-crystals (CCs) of Paliperidone (PPD) with coformers like benzoic acid (BA) and P-amino benzoic acid (PABA) were synthesized and characterized to improve the physicochemical properties and dissolution rate. CCs were prepared by the solvent evaporation (SE) technique and were compared with the products formed by neat grinding (NG) and liquid assisted grinding (LAG) in their enhancement of solubility. The formation of CCs was confirmed by the IR spectroscopy, powder X-ray diffraction and thermal analysis methods. The saturation solubility studies indicate that the aqueous solubility of PPD-BA and PPD-PABA CCs was significantly improved to 1.343±0.162mg/ml and 1.964±0.452mg/ml, respectively, in comparison with the PPD solubility of 0.473mg/ml. This increase in solubility is 2.83-and 3.09-fold, respectively. PPD exhibited a poor dissolution of 37.8% in 60min, while the dissolution of the CCs improved tremendously to 96.07% and 89.65% in 60min. CCs of PPD with BA and PABA present a novel approach to overcome the solubility challenges of poorly water-soluble drug PPD.
{"title":"Engineering cocrystals of Paliperidone with enhanced solubility and dissolution characteristics","authors":"Earle Radha-Rani, Gadela Venkata-Radha","doi":"10.5937/arhfarm71-32997","DOIUrl":"https://doi.org/10.5937/arhfarm71-32997","url":null,"abstract":"In the present study, co-crystals (CCs) of Paliperidone (PPD) with coformers like benzoic acid (BA) and P-amino benzoic acid (PABA) were synthesized and characterized to improve the physicochemical properties and dissolution rate. CCs were prepared by the solvent evaporation (SE) technique and were compared with the products formed by neat grinding (NG) and liquid assisted grinding (LAG) in their enhancement of solubility. The formation of CCs was confirmed by the IR spectroscopy, powder X-ray diffraction and thermal analysis methods. The saturation solubility studies indicate that the aqueous solubility of PPD-BA and PPD-PABA CCs was significantly improved to 1.343±0.162mg/ml and 1.964±0.452mg/ml, respectively, in comparison with the PPD solubility of 0.473mg/ml. This increase in solubility is 2.83-and 3.09-fold, respectively. PPD exhibited a poor dissolution of 37.8% in 60min, while the dissolution of the CCs improved tremendously to 96.07% and 89.65% in 60min. CCs of PPD with BA and PABA present a novel approach to overcome the solubility challenges of poorly water-soluble drug PPD.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mila Radan, J. Bošković, V. Dobričić, O. Čudina, K. Nikolić
Drug discovery and development is a very challenging, expensive and time-consuming process. Impressive technological advances in computer sciences and molecular biology have made it possible to use computer-aided drug design (CADD) methods in various stages of the drug discovery and development pipeline. Nowadays, CADD presents an efficacious and indispensable tool, widely used in medicinal chemistry, to lead rational drug design and synthesis of novel compounds. In this article, an overview of commonly used CADD approaches from hit identification to lead optimization was presented. Moreover, different aspects of design of multitarget ligands for neuropsychiatric and anti-inflammatory diseases were summarized. Apparently, designing multi-target directed ligands for treatment of various complex diseases may offer better efficacy, and fewer side effects. Antipsychotics that act through aminergic G protein-coupled receptors (GPCRs), especially Dopamine D2 and serotonin 5-HT2A receptors, are the best option for treatment of various symptoms associated with neuropsychiatric disorders. Furthermore, multi-target directed cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) inhibitors are also a successful approach to aid the discovery of new anti-inflammatory drugs with fewer side effects. Overall, employing CADD approaches in the process of rational drug design provides a great opportunity for future development, allowing rapid identification of compounds with the optimal polypharmacological profile.
{"title":"Current computer-aided drug design methodologies in discovery of novel drug candidates for neuropsychiatric and inflammatory diseases","authors":"Mila Radan, J. Bošković, V. Dobričić, O. Čudina, K. Nikolić","doi":"10.5937/arhfarm71-32523","DOIUrl":"https://doi.org/10.5937/arhfarm71-32523","url":null,"abstract":"Drug discovery and development is a very challenging, expensive and time-consuming process. Impressive technological advances in computer sciences and molecular biology have made it possible to use computer-aided drug design (CADD) methods in various stages of the drug discovery and development pipeline. Nowadays, CADD presents an efficacious and indispensable tool, widely used in medicinal chemistry, to lead rational drug design and synthesis of novel compounds. In this article, an overview of commonly used CADD approaches from hit identification to lead optimization was presented. Moreover, different aspects of design of multitarget ligands for neuropsychiatric and anti-inflammatory diseases were summarized. Apparently, designing multi-target directed ligands for treatment of various complex diseases may offer better efficacy, and fewer side effects. Antipsychotics that act through aminergic G protein-coupled receptors (GPCRs), especially Dopamine D2 and serotonin 5-HT2A receptors, are the best option for treatment of various symptoms associated with neuropsychiatric disorders. Furthermore, multi-target directed cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) inhibitors are also a successful approach to aid the discovery of new anti-inflammatory drugs with fewer side effects. Overall, employing CADD approaches in the process of rational drug design provides a great opportunity for future development, allowing rapid identification of compounds with the optimal polypharmacological profile.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pesticides are important agents that are intentionally introduced into the environment to control various pests and disease carriers, often by killing them. Although pesticides have many important objectives, including protection against crop loss and vector-borne diseases, there are significant concerns over the potential toxicity of pesticides on various organisms, including humans. The frequent use of pesticides in agriculture has led to the long-term exposure of humans to different pesticide residues. Exposure to pesticides has been linked to disturbances in the endocrine system of animals and humans. There are increasing data on the relation between lipophilic pesticides with low biodegradability and changes in reproductive functions and parameters of male and female animals. But more epidemiological and detailed information is necessary on the probability and strength of pesticide exposure-outcome relations regarding endocrine-disrupting effects.
{"title":"Endocrine disrupting mechanisms and effects of pesticides","authors":"H. Anlar, M. Bacanlı, N. Başaran","doi":"10.5937/arhfarm71-34291","DOIUrl":"https://doi.org/10.5937/arhfarm71-34291","url":null,"abstract":"Pesticides are important agents that are intentionally introduced into the environment to control various pests and disease carriers, often by killing them. Although pesticides have many important objectives, including protection against crop loss and vector-borne diseases, there are significant concerns over the potential toxicity of pesticides on various organisms, including humans. The frequent use of pesticides in agriculture has led to the long-term exposure of humans to different pesticide residues. Exposure to pesticides has been linked to disturbances in the endocrine system of animals and humans. There are increasing data on the relation between lipophilic pesticides with low biodegradability and changes in reproductive functions and parameters of male and female animals. But more epidemiological and detailed information is necessary on the probability and strength of pesticide exposure-outcome relations regarding endocrine-disrupting effects.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71199158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Machine learning algorithms, and artificial intelligence in general, have a wide range of applications in the field of pharmaceutical technology. Starting from the formulation development, through a great potential for integration within the Quality by design framework, these data science tools provide a better understanding of the pharmaceutical formulations and respective processing. Machine learning algorithms can be especially helpful with the analysis of the large volume of data generated by the Process analytical technologies. This paper provides a brief explanation of the artificial neural networks, as one of the most frequently used machine learning algorithms. The process of the network training and testing is described and accompanied with illustrative examples of machine learning tools applied in the context of pharmaceutical formulation development and related technologies, as well as an overview of the future trends. Recently published studies on more sophisticated methods, such as deep neural networks and light gradient boosting machine algorithm, have been described. The interested reader is also referred to several official documents (guidelines) that pave the way for a more structured representation of the machine learning models in their prospective submissions to the regulatory bodies.
{"title":"Review of machine learning algorithms' application in pharmaceutical technology","authors":"Jelena Đuriš, Ivana Kurćubić, S. Ibrić","doi":"10.5937/arhfarm71-32499","DOIUrl":"https://doi.org/10.5937/arhfarm71-32499","url":null,"abstract":"Machine learning algorithms, and artificial intelligence in general, have a wide range of applications in the field of pharmaceutical technology. Starting from the formulation development, through a great potential for integration within the Quality by design framework, these data science tools provide a better understanding of the pharmaceutical formulations and respective processing. Machine learning algorithms can be especially helpful with the analysis of the large volume of data generated by the Process analytical technologies. This paper provides a brief explanation of the artificial neural networks, as one of the most frequently used machine learning algorithms. The process of the network training and testing is described and accompanied with illustrative examples of machine learning tools applied in the context of pharmaceutical formulation development and related technologies, as well as an overview of the future trends. Recently published studies on more sophisticated methods, such as deep neural networks and light gradient boosting machine algorithm, have been described. The interested reader is also referred to several official documents (guidelines) that pave the way for a more structured representation of the machine learning models in their prospective submissions to the regulatory bodies.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maternal exposure to a mixture of various endocrine disruptors (EDCs) may have a substantial impact on postnatal health of her offspring(s) and increase the risk for health disorders and diseases in adulthood. Research efforts to better understand the health risk associated with endocrine disruptor exposures in early life have increased in recent decades. This paper provides a short overview of the current challenges that researchers continue to face in selecting appropriate epidemiologic methods and study designs to identify endocrine disruptors and evaluate their adverse health effects during this critical developmental window. Major challenges involve the selection of a representative biomarker that reflects the foetal internal dose of the biologically active chemical or its metabolite(s) that may be associated with adverse health effects with regard to variable level and duration of exposure and the latency between exposure and disorder/disease manifestation. Future studies should pay more attention to identifying factors that contribute to interindividual variability in susceptibility to various EDCs and other toxicants.
{"title":"Developmental toxicity of endocrine-disrupting chemicals: Challenges and future directions","authors":"A. Pizent","doi":"10.5937/arhfarm71-34457","DOIUrl":"https://doi.org/10.5937/arhfarm71-34457","url":null,"abstract":"Maternal exposure to a mixture of various endocrine disruptors (EDCs) may have a substantial impact on postnatal health of her offspring(s) and increase the risk for health disorders and diseases in adulthood. Research efforts to better understand the health risk associated with endocrine disruptor exposures in early life have increased in recent decades. This paper provides a short overview of the current challenges that researchers continue to face in selecting appropriate epidemiologic methods and study designs to identify endocrine disruptors and evaluate their adverse health effects during this critical developmental window. Major challenges involve the selection of a representative biomarker that reflects the foetal internal dose of the biologically active chemical or its metabolite(s) that may be associated with adverse health effects with regard to variable level and duration of exposure and the latency between exposure and disorder/disease manifestation. Future studies should pay more attention to identifying factors that contribute to interindividual variability in susceptibility to various EDCs and other toxicants.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71199214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patients with atrial fibrillation who had a previous transient ischemic attack or ischemic stroke had a significantly high risk of stroke recurrence and the introduction of oral anticoagulants should be mandatory. However, the long-term use of oral anticoagulants increases the risk of developing all types of intracranial hemorrhages. The advantages of non-vitamin K oral anticoagulants (NOACs) compared to warfarin are that they have a significantly lower risk for hemorrhagic stroke. They are preferred in elderly patients, those with small vessel disease, or those with previous intracerebral hemorrhage. The time of NOACs introduction after an ischemic stroke depends on its severity and the rule "1-3-6-12" days should be applied. The reintroduction of NOACs in patients with atrial fibrillation and previous intracerebral hemorrhage depends on its etiology and should be after about 4-8 weeks if the cardioembolic risk is high and the risk for intracranial hemorrhage small.
{"title":"Non-vitamin K oral anticoagulants (NOACs) in patients with stroke and atrial fibrillation","authors":"D. Jovanović","doi":"10.5937/arhfarm2005269j","DOIUrl":"https://doi.org/10.5937/arhfarm2005269j","url":null,"abstract":"Patients with atrial fibrillation who had a previous transient ischemic attack or ischemic stroke had a significantly high risk of stroke recurrence and the introduction of oral anticoagulants should be mandatory. However, the long-term use of oral anticoagulants increases the risk of developing all types of intracranial hemorrhages. The advantages of non-vitamin K oral anticoagulants (NOACs) compared to warfarin are that they have a significantly lower risk for hemorrhagic stroke. They are preferred in elderly patients, those with small vessel disease, or those with previous intracerebral hemorrhage. The time of NOACs introduction after an ischemic stroke depends on its severity and the rule \"1-3-6-12\" days should be applied. The reintroduction of NOACs in patients with atrial fibrillation and previous intracerebral hemorrhage depends on its etiology and should be after about 4-8 weeks if the cardioembolic risk is high and the risk for intracranial hemorrhage small.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory and cognitive function impairment as well as behavioural and psychiatric disturbances. Pharmaceutical care involves the process of identifying, resolving, and preventing drug-related problems, and it is aimed at improving the patient’s quality of life. AD is usually diagnosed in elderly patients with comorbidities and, consequently, a variety of drug-related problems may occur. Pharmacists should focus on adverse reactions, drug-drug interactions, and adherence in patients with AD. The introduction of acetylcholinesterase inhibitors in treatment may be associated with adverse effects, such as diarrhoea, muscle cramps, fatigue, nausea, vomiting, insomnia, anorexia, headache, and dizziness, which may be transient or require an alternative medication. Use of anticholinergic medications, bradycardia causing medications, antipsychotics and other medications should be assessed carefully because of potential drug-drug interactions with acetylcholinesterase inhibitors, especially rivastigmine. Adherence may be a major drugrelated problem in patients with AD because of the nature of illness and appropriate communication between pharmacists and patients or carers requiring adequate skills and knowledge. Although AD is increasing in prevalence there is a lack of evidence about the impact of pharmaceutical care on the treatment outcomes and quality of life of patients and more research is needed in this area.
{"title":"Pharmaceutical care in Alzheimer's disease","authors":"Sandra Vezmar-Kovačević","doi":"10.5937/arhfarm2002069v","DOIUrl":"https://doi.org/10.5937/arhfarm2002069v","url":null,"abstract":"Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory and cognitive function impairment as well as behavioural and psychiatric disturbances. Pharmaceutical care involves the process of identifying, resolving, and preventing drug-related problems, and it is aimed at improving the patient’s quality of life. AD is usually diagnosed in elderly patients with comorbidities and, consequently, a variety of drug-related problems may occur. Pharmacists should focus on adverse reactions, drug-drug interactions, and adherence in patients with AD. The introduction of acetylcholinesterase inhibitors in treatment may be associated with adverse effects, such as diarrhoea, muscle cramps, fatigue, nausea, vomiting, insomnia, anorexia, headache, and dizziness, which may be transient or require an alternative medication. Use of anticholinergic medications, bradycardia causing medications, antipsychotics and other medications should be assessed carefully because of potential drug-drug interactions with acetylcholinesterase inhibitors, especially rivastigmine. Adherence may be a major drugrelated problem in patients with AD because of the nature of illness and appropriate communication between pharmacists and patients or carers requiring adequate skills and knowledge. Although AD is increasing in prevalence there is a lack of evidence about the impact of pharmaceutical care on the treatment outcomes and quality of life of patients and more research is needed in this area.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This paper presents study of losartan potassium stability evaluation by liquid chromatography with UV/VIS and MS-MS detection and its degradation profile. A solution of losartan potassium was exposed to the following stress agents: 0.1 M HCl, 0.1 M NaOH, and 3% (v/v) H2O2. The analyses of losartan potassium solutions were carried out in a gradient elution mode with acetonitrile and 0.1% (v/v) CF3COOH aqueous solution and constant flow rate of 0.5 mL min within 22 min run time. After 7 days of losartan potassium solutions exposure to the stress agents at room temperature, it was found that the degree of degradation in the presence of 0.1 M HCl and 0.1 M NaOH was less than 1%, while in the presence of 3% H2O2 degradation was significantly higher (about 10%). Chemical structure elucidation of the major degradation products of losartan potassium was performed using LC-MS/MS method. The concentration versus time plot indicated that in 3% (v/v) H2O2 solution losartan potassium was degraded according to the pseudo zero-order reaction kinetics with 1.48ꞏ10 mol L day rate constant.
本文研究了氯沙坦钾稳定性的液相色谱-紫外/可见和质谱联用检测及其降解谱。将氯沙坦钾溶液暴露于以下应激剂中:0.1 M HCl, 0.1 M NaOH和3% (v/v) H2O2。氯沙坦钾溶液以乙腈和0.1% (v/v) CF3COOH水溶液梯度洗脱，恒流量0.5 mL min，运行时间22 min。氯沙坦钾溶液在室温下暴露于胁迫剂7天后，发现0.1 M HCl和0.1 M NaOH存在时降解程度小于1%，而3% H2O2存在时降解程度明显较高(约为10%)。采用LC-MS/MS法对氯沙坦钾的主要降解产物进行了化学结构分析。浓度-时间曲线表明，在3% (v/v) H2O2溶液中，氯沙坦钾的降解符合伪零级反应动力学，日速率常数为1.48ꞏ10 mol L。
{"title":"Degradation kinetics and characterization of degradation products of losartan potassium by LC-MS/MS method","authors":"V. Dobričić, B. Marković","doi":"10.5937/arhfarm1902080x","DOIUrl":"https://doi.org/10.5937/arhfarm1902080x","url":null,"abstract":"This paper presents study of losartan potassium stability evaluation by liquid chromatography with UV/VIS and MS-MS detection and its degradation profile. A solution of losartan potassium was exposed to the following stress agents: 0.1 M HCl, 0.1 M NaOH, and 3% (v/v) H2O2. The analyses of losartan potassium solutions were carried out in a gradient elution mode with acetonitrile and 0.1% (v/v) CF3COOH aqueous solution and constant flow rate of 0.5 mL min within 22 min run time. After 7 days of losartan potassium solutions exposure to the stress agents at room temperature, it was found that the degree of degradation in the presence of 0.1 M HCl and 0.1 M NaOH was less than 1%, while in the presence of 3% H2O2 degradation was significantly higher (about 10%). Chemical structure elucidation of the major degradation products of losartan potassium was performed using LC-MS/MS method. The concentration versus time plot indicated that in 3% (v/v) H2O2 solution losartan potassium was degraded according to the pseudo zero-order reaction kinetics with 1.48ꞏ10 mol L day rate constant.","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Stefanović, A. Zeljković, J. Vekić, V. Spasojević-Kalimanovska, Z. Jelić-Ivanović, S. Spasić
{"title":"Dyslipidemia in type 2 diabetes mellitus","authors":"A. Stefanović, A. Zeljković, J. Vekić, V. Spasojević-Kalimanovska, Z. Jelić-Ivanović, S. Spasić","doi":"10.5937/arhfarm1905338s","DOIUrl":"https://doi.org/10.5937/arhfarm1905338s","url":null,"abstract":"","PeriodicalId":39173,"journal":{"name":"Arhiv za Farmaciju","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71198741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：